0.4700USD0.00%Mkt Cap: 19.17M USDP/E: —Last update: 2026-06-01
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the U…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap19.17M USD
Enterprise Value10.13M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.48M USD
Revenue/Share—
Last Price0.4700 USD
Fiscal Year EndJun 2025
MR QuarterDec 2025
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.72
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.44
EPS (TTM)-0.18
EPS (Forward)-0.65
52W Range
0.30005% of range3.420
52W High3.420 USD
52W Low0.3000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-72.78%
ROA-69.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.35M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-19.69%
Net Debt-9.04M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio6.24
Quick Ratio6.12
Book Value/Sh0.1930 USD
Cash/Share0.2220 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.40.78M
Float24.13M
Insiders40.84%
Institutions0.00%
Short Interest
Short Ratio1.5d
Short % Float2.20%
Short % Out.0.36%
Shares Short146.37K
Short (prev mo.)58.05K
Technical
SMA 500.6076 (-22.6%)
SMA 2001.501 (-68.7%)
Beta-1.94
S&P 52W Chg27.94%
Avg Vol (30d)2.55K
Avg Vol (10d)4.28K
Technical Indicators
RSI (14)47.5
MACD-0.0251
MACD Signal-0.0290
MACD Hist.+0.0039
BB Upper0.5244 USD
BB Middle0.4692 USD
BB Lower0.4140 USD
BB Width23.53%
ATR (14)0.0550 USD
Vol Ratio (20d)0.04x